for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-WHO Says Solidarity Therapeutics Trial Produces Conclusive Evidence On Effectiveness Of Repurposed Drugs For COVID-19 In Record Time

Oct 15 (Reuters) -

* WHO SAYS SOLIDARITY THERAPEUTICS TRIAL PRODUCES CONCLUSIVE EVIDENCE ON EFFECTIVENESS OF REPURPOSED DRUGS FOR COVID-19 IN RECORD TIME

* WHO SAYS INTERIM REMDESIVIR, HYDROXYCHLOROQUINE, LOPINAVIR/RITONAVIR AND INTERFERON REGIMENS APPEARED TO HAVE LITTLE OR NO EFFECT ON 28-DAY MORTALITY

* WHO-INTERIM RESULTS IN TRIAL INDICATE REMDESIVIR APPEARED TO HAVE LITTLE OR NO EFFECT ON 28DAY MORTALITY OR IN-HOSPITAL COURSE OF COVID-19 IN PATIENTS

* WHO- STUDY, WHICH SPANS OVER 30 COUNTRIES, LOOKED AT EFFECTS OF TREATMENTS ON OVERALL MORTALITY, INITIATION OF VENTILATION, DURATION OF HOSPITAL STAY

* WHO - NEWER ANTIVIRAL DRUGS, IMMUNOMODULATORS AND ANTI-SARS COV-2 MONOCLONAL ANTIBODIES ARE NOW BEING CONSIDERED FOR EVALUATION AT SOLIDARITY TRIAL Source text: bit.ly/354EyBs

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up